Local steroid injection for moderately severe idiopathic carpal tunnel syndrome: Protocol of a randomized double-blind placebo-controlled trial (NCT 00806871) by Flondell, Magnus et al.
Flondell et al. BMC Musculoskeletal Disorders 2010, 11:76
http://www.biomedcentral.com/1471-2474/11/76
Open Access STUDY PROTOCOL
BioMed  Central
© 2010 Flondell et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Study protocol Local steroid injection for moderately severe 
idiopathic carpal tunnel syndrome: Protocol of a 
randomized double-blind placebo-controlled trial 
(NCT 00806871)
Magnus Flondell*1,2, Manfred Hofer3, Jonas Björk4 and Isam Atroshi1,2
Abstract
Background: Patients with idiopathic carpal tunnel syndrome (CTS) are commonly treated with steroid injection into 
or proximal to the carpal tunnel. However, evidence for its efficacy beyond one month has not been established in 
randomized placebo-controlled trials. The primary aim of this randomized trial is to assess the efficacy of steroid 
injection into the carpal tunnel in relieving symptoms of CTS in patients with symptoms of such severity to warrant 
surgical treatment but have not been treated with steroid injection.
Methods/Design: The study is a randomized double-blind placebo-controlled trial. Patients referred to one 
orthopedic department because of CTS are screened. Eligibility criteria are age 18 to 70 years, clinical diagnosis of 
primary idiopathic CTS and abnormal nerve conduction tests or clinical diagnosis made independently by two 
orthopedic surgeons, failed treatment with wrist splinting, symptom severity of such magnitude that the patient is 
willing to undergo surgery, no severe sensory loss or thenar muscle atrophy, and no previous steroid injection for CTS. 
A total of 120 patients will be randomized to injection of 80 mg Methylprednisolone, 40 mg Methylprednisolone, or 
normal saline, each also containing 10 mg Lidocaine. Evaluation at baseline and at 5, 10, 24 and 52 weeks after injection 
includes validated questionnaires (CTS symptom severity scale, QuickDASH and SF-6D), adverse events, physical 
examination by a blinded assessor, and nerve conduction tests. The primary outcome measures are change in the CTS 
symptom severity score at 10 weeks and the rate of surgery at 52 weeks. The secondary outcome measures are the 
score change in the CTS symptom severity scale at 52 weeks, time to surgery, and change in QuickDASH and SF-6D 
scores and patient satisfaction at 10 and 52 weeks. The primary analysis will be carried out using mixed model analysis 
of repeated measures.
Discussion: This paper describes the rationale and design of a double-blind, randomized placebo-controlled trial that 
aims to determine the efficacy of two different doses of steroid injected into the carpal tunnel in patients with 
moderately severe idiopathic CTS.
Trial registration: Clinicaltrials.gov identifier NCT00806871
Background
Carpal tunnel syndrome (CTS) is the most common
peripheral compression neuropathy in the upper extrem-
ity with a prevalence of 3.7% in the adult general popula-
tion [1]. The prevalence of persons who have moderate or
severe CTS but have not sought care or been diagnosed
correctly is almost 1% in the general population [2]. CTS
of mild severity is commonly treated with wrist splint but
for moderately severe symptoms surgical treatment is
often required [3]. Carpal tunnel release is one of the
most common surgical procedures; the annual incidence
in a US population (2001-2005) was 134 per 100,000 [4]
Although carpal tunnel release has been shown to pro-
duce good outcomes regarding relief of symptoms caused
by CTS [5], it has several disadvantages including sur-
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gery-related pain and hand weakness [6]. These are com-
mon problems and may last several months after surgery.
Other less common complications include wound infec-
tion, chronic regional pain syndrome, and nerve injuries
[7,8]. In addition, surgery is associated with direct costs
as well as indirect costs related to work absence after sur-
gery because the majority of patients require sick leave
for a varying length of time depending on the degree of
postoperative morbidity and the type of work [9]. The
median time of work absence has been 4 weeks in several
studies, with a proportion of patients having long-term
work disability [9]. The economic impact of work absence
following surgery for CTS can be substantial both for the
patients and the society. Consequently avoiding sick leave
would be an important advantage for nonsurgical treat-
ment.
Although many alternatives to surgery have been pro-
posed there is little evidence to support the efficacy of
most of these treatments [10]. Steroid injection into or
proximal to the carpal tunnel is widely practiced in the
treatment of patients with idiopathic CTS particularly in
the United States [11]. However, the evidence for its effi-
cacy beyond one month has not been established in pla-
cebo-controlled trials. In a recent Cochrane review of
local corticosteroid injection for CTS, the authors con-
cluded that there was evidence supporting clinical
improvement at one month compared to placebo but no
significant improvement after 8 weeks compared to non-
steroidal anti-inflammatory drugs or wrist splint [12].
None of the studies reviewed involved a double-blind
comparison with a follow-up of more than one month.
Because of the strong evidence supporting the efficacy
of surgery, randomized studies that compared steroid
injections with surgery may provide indirect measure of
the efficacy of steroid injection. One such study of 163
wrists comparing surgery with steroid injection (84%
received 2 injections within 2 weeks) reported similar
effects up to 1 year but outcomes were not assessed with
validated CTS-specific measures and it did not compare
the full effect size of surgery with that of steroid injection
as the primary outcome but rather the proportion of
patients in each group that achieved modest improve-
ment [13]. Previous studies comparing steroid injection
with surgery have not specifically involved patients
whose CTS was of such severity that surgery was clearly
indicated. Obviously, if the study population includes
many patients with less severe CTS the comparison may
be biased. Because the main effects of treatment are
improvements in symptoms and in hand function it is
important that these outcomes be evaluated with reliable
and valid measures [14,15]. The use of steroid injection as
a routine treatment in patients with CTS would incur
costs and, if ineffective, would prolong patients' disability
and delay surgery that usually results in rapid symptom
improvement.
In patients with CTS secondary to rheumatoid arthritis
the use of steroid injection is based on the assumption
that flexor tenosynovitis is the causative factor. This is
probably the theoretical basis for using steroid injection
even in idiopathic CTS although no such etiological rela-
tionship has been established. To our knowledge, the effi-
cacy of local steroid injection in CTS has not been
investigated in randomized trials with regard to the pos-
sible presence of a dose-response relationship.
There is currently no evidence to support the efficacy
of carpal tunnel steroid injection in relieving symptoms
of idiopathic CTS for up to 1 year as measured with vali-
dated CTS-specific symptom measures and no evidence
of possible dose-response relationship.
Methods/Design
Design
The trial is a prospective randomized double-blind pla-
cebo-controlled dose-response clinical trial comparing
injection of 40 mg Methylprednisolone, 80 mg Methyl-
prednisolone or placebo into the carpal tunnel in patients
with moderately severe idiopathic CTS not previously
treated with steroid injection.
Inclusion Criteria
The inclusion criteria (Table 1) are primary, idiopathic
CTS, age 18 to 70 years, either gender, symptoms of clas-
sic or probable CTS according to the diagnostic criteria in
the Katz hand diagram [16], symptom duration of at least
3 months, inadequate response to wrist splint, nerve con-
duction tests showing median neuropathy at the wrist
and no other abnormalities or, in the presence of normal
nerve conduction test results, two orthopedic surgeons
independently diagnose the patient with CTS, and symp-
tom severity of such magnitude that the patient is willing
to undergo surgery.
Exclusion Criteria
The exclusion criteria are previous steroid injection for
CTS in the same wrist, severe sensory loss (two-point
discrimination exceeding 8 mm), thenar atrophy, inflam-
matory joint disease, diabetes mellitus, vibration-induced
neuropathy, polyneuropathy, pregnancy, trauma to the
affected hand in the previous year, previous surgery for
CTS in the affected hand, surgery for CTS in the contral-
ateral hand within the past 2 months, inability to respond
to questionnaires (e.g., because of language difficulty or
cognitive impairment), severe medical illness, and known
abuse of drugs or alcohol.Flondell et al. BMC Musculoskeletal Disorders 2010, 11:76
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Recruitment
Patients referred by primary care physicians to one
orthopedic department (Hässleholm and Kristianstad
Hospitals) are examined by trial investigators (orthopedic
surgeons) at the outpatient clinic and screened for eligi-
bility. Those with a clinical diagnosis of CTS who have
failed treatment with wrist splint and whose symptom
severity is judged to warrant surgery are offered to be put
on the waiting list for carpal tunnel release. Patients who
are willing to undergo surgery are put on the waiting list,
which means a waiting time of approximately 3 months.
The trial investigator explains the aims, advantages and
disadvantages of the trial to eligible patients at the ortho-
pedic department's outpatient clinic. Patients who give
informed consent will be allocated to one of the three
trial groups. Recruited patients are assigned to a treat-
ment group at the outpatient clinic according to a com-
puter-generated randomization list. Immediately
following the allocation the patients will receive the
assigned treatment. In patients with bilateral symptoms
the most symptomatic hand (as reported by the patient)
will be included and in case both hands are equally symp-
tomatic the dominant hand will be included. Patients will
not be allowed to enter the trial more than once.
Recruitment to the trial according to the plan described
above is believed to ensure the inclusion of a representa-
tive sample from the patient population residing in the
catchment area. All patients are asked for informed con-
sent before any study procedure is performed. The
patients will be recorded in a screening/inclusion/ran-
domization list.
Ethics
This trial has been approved by the Ethics Committee at
the Faculty of Medicine, Lund University (Nr 119-2008)
and the Swedish Medical Products Agency (EU 2008-
001871-31). The trial will be conducted in full compli-
ance with the Helsinki Declaration.
Randomization
A computer-generated randomization list of 120 items in
blocks of variable sizes (unknown to the investigators
involved in recruiting patients) is prepared by the statisti-
cian. Based on the list sequentially numbered sealed
opaque envelopes containing cards with group assign-
ments are prepared. These sealed envelopes marked with
the patients' sequential numbers are kept at the orthope-
dic department's outpatient clinic. When a patient is
enrolled and written informed consent obtained, the
nurse opens the envelope with the lowest number and
prepares the injection according to the card and then sign
date, name and sequential number on the medication list.
The nurse preparing the drug is responsible for putting
the card in a new envelope marked with the sequential
number . This card will be kept in a box with the study
medication. As backup, a sealed envelope with the ran-
domization database is kept, together with the study
drugs, in the locked area reserved for drugs at the outpa-
tient department. In case the blinding needs to be broken
for a patient, the nurse will open the envelope and extract
the information for that patient. The envelope will be
signed with name and date and given to a monitor.
Interventions
Group A: 1 ml 40 mg Methylprednisolone (Depomedrol
40 mg/ml) + 1 ml 10 mg Lidocaine (Xylocain 10 mg/ml) +
1 ml saline (NaCl Bayer)
Group B: 2 ml 80 mg Methylprednisolone (Depomedrol
40 mg/ml) + 1 ml 10 mg Lidocaine (Xylocain 10 mg/ml)
Group C: 1 ml 10 mg Lidocaine (Xylocain 10 mg/ml) +
2 ml saline (NaCl Bayer)
The mixture of drugs is prepared by the nurse in the
outpatient orthopedic department. This mixture of drugs
is standard procedure for Methylprednisolone injection
and all nurses have experience in performing this task.
The drugs will be injected subfascially in the soft tissue of
Table 1: Eligibility criteria
Inclusion criteria Exclusion criteria
Primary, idiopathic CTS Previous steroid injection in 
same wrist
Age 18-70 years Inflammatory joint disease
Either gender Diabetes mellitus
Classic or probable CTS 
according to the diagnostic 
criteria in the Katz hand 
diagram
Polyneuropathy
Symptom duration of at least 
3 months
Vibration induced 
neuropathy
Inadequate response to wrist 
splint
Pregnancy
Abnormal nerve conduction 
tests or, if normal, CTS 
diagnosed independently by 
2 surgeons
Trauma to affected hand in 
preceding year
Patient willing to undergo 
surgery
Previous surgery for CTS on 
affected hand
Surgery for CTS on 
contralateral hand in 
preceding 2 months
Inability to respond to 
questionnaires
Severe sensory loss (two-
point discrimination >8 mm)
Thenar atrophy
Severe medical illness
Drug or alcohol abuseFlondell et al. BMC Musculoskeletal Disorders 2010, 11:76
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the carpal canal once by the investigator at baseline
according to a previously described injection technique
[17]. After injection, patients are instructed to use their
hands normally as tolerated; no instructions are given
regarding specific activity modifications or splint use.
Evaluations
At baseline and the last follow-up (Table 2) median nerve
conduction testing of both hands is performed. The mea-
surements include median nerve motor distal latency and
sensory conduction velocity across the carpal tunnel,
median nerve index finger-wrist sensory latency, or ring
finger-wrist median-ulnar sensory latency difference.
At baseline and at three follow-up occasions a physical
examination is performed by the same physical therapist
with extensive experience in hand therapy. Semmes-
Weinstein monofilament and two-point discrimination
tests of sensation are performed on the radial and ulnar
aspects of each finger; two-point discrimination testing
starts with a distance of 4 mm that is successively
increased by 2 mm until the correct tactile discrimination
is recorded. Grip strength and 3-point pinch strength are
measured with the Baseline dynamometer and pinch
gauge (Chattanooga Group, Hixson, Tennessee, USA),
respectively (three trials for each hand). Before examina-
tion, the patients are instructed not to discuss their treat-
ment with the assessor and will have their palms covered
with a dressing to conceal possible scar after carpal tun-
nel release. The assessor is thus blinded to whether the
patient had or had not undergone surgery after the injec-
tion. At the 10-week examination the success of blinding
is evaluated by asking the examiner and patient to record
whether they think the patient had received active treat-
ment. After the 52-week physical examination the patient
will proceed to nerve conduction testing keeping the
s a m e  p a l m  d r e s s i n g  s o  t h a t  t h e  e x a m i n e r  a l s o  w i l l  b e
blinded.
Follow-up
At the Baseline visit, demographics, earlier and ongoing
disease, and concomitant medication are recorded. The
baseline data include weight, height, and smoking and
employment status. The patient completes a question-
naire that includes demographic data, the CTS symptoms
severity scale, the 11-item disabilities of the arm, shoul-
der and hand (QuickDASH) questionnaire, and the SF-
6D. A physical examination is performed.
At 5 weeks after injection a telephone interview is con-
ducted by the investigator and the patient is asked to
complete the CTS symptoms severity scale and concomi-
tant medication and adverse events (AEs) will be
recorded.
Table 2: Patient visits in the trial, data collection and outcome measures
Pre-screen Baseline 5 wk +5 d 10 wk ± 7 d 12 wk† ± 7 d 24 wk ± 7 d 52 wk ± 7 d
Diagnosis, 
inclusion & 
exclusion 
criteria
X
Demographics X
Randomization X
Physical 
examination*
XXX X
Nerve 
conduction 
testing
X X
Outcome 
questionnaires
XXX XX
Rate of surgery XXX
Sick-leave 
report
XXX XX
Adverse events X X X X
Study 
medication
X
Concomitant 
medication
XXX X
*Two-point discrimination, monofilament test, grip and pinch strength
†Surgery in participants choosing to have surgeryFlondell et al. BMC Musculoskeletal Disorders 2010, 11:76
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At 10 weeks after injection the patient is examined by
the physical therapist. The investigator asks the patient
whether she/he wants to proceed with surgery as planned
at 12 weeks after injection or whether the patient has
experienced adequate symptom relief that she/he wants
to continue follow-up and not have the planned surgery
at this stage. An evaluation similar to the baseline evalua-
tion is performed and the indication for surgery is
recorded. The patient completes the CTS symptoms
severity scale. Concomitant medication and AEs are
recorded. Possible use of a wrist splint since the injection
and its frequency is recorded.
At 12 weeks the patient who had chosen to have sur-
gery is operated on as scheduled.
At 24 weeks after injection the patient is examined and
asked to complete a questionnaire including the CTS
symptoms severity scale, QuickDASH, and the SF-6D as
well as to rate satisfaction with the treatment on a visual
analog scale from 0 (very dissatisfied) to 100 (completely
satisfied). Concomitant medication and AEs are
recorded.
At 52 weeks after injection the patient is asked to attend
a physical examination and nerve conduction tests and
complete the questionnaires.
Outcome Measures
The CTS symptoms severity scale is a validated 11-item
questionnaire that mainly inquires about severity, fre-
quency and duration of night and daytime pain and
numbness or tingling [14,15]. The CTS score ranges from
1 (no symptoms) to 5 (most severe symptoms). The
QuickDASH is a validated 11-item questionnaire that
mainly inquires about difficulties in performing daily
activities, yielding a score from 0 (no disability) to 100
(worst possible disability) [18]. The SF-6D is a validated
health utility measure that is used to compare cost-effec-
tiveness of different treatments and the value ranges from
-0.11 (worst health) to 1.0 (perfect health) [19]. All AEs
are recorded during 24 weeks. Duration of sick leave for
employed patients is recorded.
Blinding
The nurse at the outpatient clinic prepares the medica-
tion with a label covering the syringe. The injection will
then be administered to the patient by the investigator.
The placebo is clear and Methylprednisolone is a white
suspension. In subfascial injections such as in the carpal
canal leakage from the injection canal is small. The inves-
tigator administering the injection presses a medical
dressing over the puncture site while withdrawing the
needle; this will conceal the color in case of leakage. The
decision whether or not to have surgery is done by the
patient at 10 weeks and the patients are instructed to
make that choice based on their symptoms and func-
tional status at that time. At the 24-week and 52-week
patient visits the palm is covered by a bandage with a
dressing to blind the examining physical therapist as to
whether the patient had undergone surgery after the
injection. All follow-up evaluations are done by a physical
therapist blinded to the group assignment.
Sample Size
Based on previous studies of surgical outcome in patients
with idiopathic CTS the mean improvement in the CTS
symptom severity scale at 12 weeks after surgery is about
1.6 (on the 1 to 5 point scale). A mean improvement of
less than 0.8 in the CTS symptom severity score cannot
warrant recommending steroid injection as an effective
alternative treatment. With 90% statistical power, 5% sig-
nificance level, and two-sided statistical tests, and assum-
ing a standard deviation of 1.0 for the CTS symptom
severity score the study can detect a true difference of at
least 0.8 point on the CTS symptom severity score
between an intervention group and the placebo group
when 102 patients have been randomized. The aim will
be to enroll 120 patients in the study to account for
potential incomplete follow-ups.
Primary endpoint
1. The CTS symptom severity score change at 10 weeks
after treatment:
1) 80 mg Methylprednisolone vs. placebo
2) 40 mg Methylprednisolone vs. placebo
3) 80 mg Methylprednisolone vs. 40 mg Methylpred-
nisolone
2. The rate of surgery at (in rank order) 52 weeks, 24
weeks, and 12 weeks after treatment:
1) 80 mg Methylprednisolone vs. placebo
2) 40 mg Methylprednisolone vs. placebo
3) 80 mg Methylprednisolone vs. 40 mg Methylpred-
nisolone
Secondary endpoint
1. The CTS symptom severity score change at 52 weeks
2. Time to surgery
3. The QuickDASH score at 10 weeks and 52 weeks
4. The SF-6D score at 10 weeks and 52 weeks
5. Patient satisfaction with treatment at 10 weeks and
52 weeks
6. Duration of sick leave at 52 weeks (for employed
patients)
Statistical Analysis
All patients who have been randomized and have
received an injection will be included in the statistical
evaluation. Statistical tests will be performed and
reported according to the intention-to-treat principle.
Data will be presented as mean and standard deviation or
median and range, as appropriate, for continuous vari-Flondell et al. BMC Musculoskeletal Disorders 2010, 11:76
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ables and as numbers and proportions for categorical
variables. The primary analysis of the CTS symptom
severity score at 10 weeks will be performed using a
mixed model analysis of repeated measures (baseline, 5
weeks, 10 weeks) with treatment effect (placebo or Meth-
ylprednisolone) and time as fixed factors in a first step
and with the interaction term of treatment and time in
second step. The results will be presented as differences
in mean score change over time (baseline to 10 weeks)
and 95% confidence intervals. The secondary analysis of
the symptom severity score will be done using a mixed
model with treatment (placebo or Methylprednisolone)
as a random factor and time (baseline, 5 weeks, 10 weeks,
24 weeks, 52 weeks) as fixed factor and surgery as covari-
ate; first step without interaction terms and second step
with two-way interaction of treatment and time. The
results will be presented as differences in mean score
change over time and 95% confidence intervals.
The primary analysis of rate of surgery will be done
using Fisher's exact test (univariate) and logistic regres-
sion (multivariate) with adjustment for baseline variables.
The issue of multiplicity is addressed by performing the
analysis in the following priority; 52 weeks, 24 weeks, and
12 weeks. The results will be presented as differences in
the rate of surgery between the groups (Methylpredniso-
lone compared with placebo) and as adjusted odds ratio
(and 95% confidence interval) of having surgery at each
time point. The possible dose-response relationship with
higher effect of high dose will be explored by prioritizing
group comparisons. We will conduct the following pre-
defined subgroup analyses; symptom duration (12
months or shorter versus more than 12 months), symp-
tom severity (baseline symptom severity score below 3.0
versus 3.0 or higher), and median nerve conduction
abnormality (moderate or severe versus mild or normal).
Analysis of the secondary end-points will be done with
mixed models adjusting for baseline variables. We will
also calculate the effect size for the symptom and func-
tion scales [20]. The AEs will be reported in table form
and stratified in 4 groups according to severity; statistical
comparison will be done when appropriate. When at least
60 patients have completed the 24-week visit the fre-
quency of SAEs and of AEs with persistent symptoms will
be calculated and the results will be reported and dis-
cussed with the Swedish Medical Products Agency.
Discussion
In this double-blind placebo-controlled randomized trial
of patients with moderately severe idiopathic CTS we
intend to investigate the medium-term efficacy of steroid
injection into the carpal tunnel and the possible presence
of a dose-response relationship first at 10 weeks but also
at 24 weeks and 52 weeks. The strength of this trial is that
it will be performed at one orthopedic department to
which the vast majority of patients with CTS from the
study region are referred. In addition, steroid injection is
rarely used as a treatment for primary idiopathic CTS by
primary care physicians who usually treat patients with
CTS in the study region before referring them to the
orthopedic department.
A potential factor that may influence the results is that
all patients are given the choice to have surgery at 12
weeks if their symptoms have not improved adequately.
Before inclusion in the trial all the patients have unsuc-
cessfully undergone treatment with wrist splinting and
have symptoms of such severity that warranted referral to
the orthopedic department. Because surgery is the only
remaining treatment option with a strong evidence of
efficacy there is no ethically acceptable alternative to
offering surgery after 12 weeks. This trial will not answer
the question of whether steroid injection is effective in
patients with CTS that failed wrist splinting but the
severity of which is judged by the patient as mild and not
warranting surgery or in patients declining surgery for
other reasons. The use of the standardized CTS symptom
severity scale in the trial will show the severity spectrum
of CTS in the study population. Another factor is the
potential multiplicity of the analyses but this is addressed
by providing a rank order with which the analyses will be
carried out.
Our goal is to determine the efficacy of two different
doses of local steroid injection in the treatment of moder-
ately severe CTS, taking into account the natural course
of CTS and the placebo effect of injection. During the
first 24 weeks the safety of steroid injection in the carpal
tunnel will also be evaluated in comparison with placebo.
The results will also be useful to predict the effect of
treatment with steroid injection related to severity of
CTS. Information on possible relationship between dos-
age and duration of effect also will be provided by this
study.
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